Ipsen has added a six-month triptorelin depot injection to its Decapeptyl SR range.
The 22.5mg presentation is licensed for the treatment of metastatic prostate cancer and for locally advanced, non-metastatic prostate cancer as an alternative to surgical castration.
It is supplied as a powder and solvent for suspension, to be administered by intramuscular injection.
Decapeptyl SR is also available in 1-monthly (3mg) and 3-monthly (11.25mg) presentations for the treatment of precocious puberty and endometriosis.
Further information: Ipsen